ISMOTIC by Alcon is clinical pharmacology isosorbide is rapidly absorbed after oral administration. First approved in 1974.
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
ISMOTIC (isosorbide) is an oral osmotic solution approved in 1974 that works by drawing water into the circulatory system and promoting urinary elimination. The drug is rapidly absorbed, remains essentially unmetabolized, and acts as an osmotic agent to redistribute water toward the bloodstream. It is indicated for conditions requiring osmotic diuresis, primarily intraocular pressure reduction in ophthalmology.
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling a contracting brand team focused on market defense rather than expansion.
CLINICAL PHARMACOLOGY Isosorbide is rapidly absorbed after oral administration. It is essentially nonmetabolized, and in the circulation, it contributes to the tonicity of the blood until it is eliminated by the kidney unchanged. While in the blood, isosorbide acts as an osmotic agent to promote…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ISMOTIC positions you in a mature, niche ophthalmology franchise with minimal growth trajectory and zero linked job openings, indicating a small or consolidating team. Career development on this product requires expertise in market defense, managed care negotiation, and specialist relationship management rather than growth launches.
Worked on ISMOTIC at Alcon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.